Samsung Bioepis Co., Ltd. vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding IPR2023-00442 filed by Samsung Bioepis Co., Ltd. on 2023-01-06. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2023-00442
Filing Date
2023-01-06
Accorded Filing Date
2023-01-06
Institution Decision Date
2023-07-19
Last Modified Date
2024-08-23
Proceeding Type
IPR
Termination Date
2024-06-14
Trial Status
Final Written Decision
Parties & Counsel
Petitioner
Samsung Bioepis Co., Ltd.
Represented By
Nimrod, Raymondet alPatent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Fishman, Deborahet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Final Written Decision
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 18 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 10,130,681 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,857,205 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,828,345 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,888,601 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,986,511 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,730,794 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,975,045 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,707,506 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,253,572 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,559,564 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,268,730 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2025015266 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011614322 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011614348 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011615619 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.